Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases.
Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Company Details
- Employees
- 32
- Founded
- -
- Address
- 15, Chemin Du Saquin, Espace Européen, Building G, Ecully,69130,france
- Phone
- 33 4 72 18 94 28
- co****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- amolytpharma.com
- Keywords
- Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, Endocrine Disease, Rare Disease.
- HQ
- Ecully
Amolyt Pharma Questions
Amolyt Pharma's helpline number is 33 4 72 18 94 28
Amolyt Pharma's website is amolytpharma.com
Amolyt Pharma's LinkedIn profile is https://www.linkedin.com/company/amolytpharma
Amolyt Pharma has
32 employees.
View email and phone details for 32
employees at Amolyt Pharma.
Amolyt Pharma's industry is
Biotechnology Research
Amolyt Pharma's top competitors are
Imcheck Therapeutics,
Vertex Pharmaceuticals,
Enterome,
Abivax,
Enyo Pharma,
Alexion Pharmaceuticals, Inc.,
Astrazeneca,
Portola Pharmaceuticals,
Achillion Pharmaceuticals, Inc.,
Innate Pharma.
Amolyt Pharma's support email address is contact@alz-pharma.com
Amolyt Pharma's categories are Biotechnology Research
Amolyt Pharma's founding year is 2015
